Dan Spiegelman
Director/Board Member at KYVERNA THERAPEUTICS, INC.
Net worth: 863 311 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christopher Henney | M | 83 |
Xcyte Therapies, Inc.
| 19 years |
| Richard D. van Doren | M | 47 |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 8 years |
| Louis Lange | M | 72 |
Recardia Therapeutics, Inc.
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 20 years |
| Fred Cohen | M | 67 |
Stanford University
| 11 years |
| Srini Akkaraju Akkaraju | M | 56 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 8 years |
| Charles Homcy | M | 75 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | - |
| Dominic Borie | M | 61 | 4 years | |
| Michael Grey | M | 71 | 7 years | |
| Paul Diaz | M | 61 | 4 years | |
| Jason V. Coloma | M | - |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | - |
| Judith Robertson | F | 64 | 3 years | |
| Camilla Simpson | F | 52 | 10 years | |
| Christine O'Brien | F | - |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | 9 years |
| Cory Freedland | M | 48 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 7 years |
| Perry Karsen | M | 69 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 years |
| S. Phanstiel | F | 65 | 15 years | |
| Rashmi Kumar | F | 53 | 4 years | |
| Dale Muzzey | M | 44 | 10 years | |
| Bali Muralidhar | M | 44 | 4 years | |
| Willard Dere | M | 70 | 8 years | |
| Elizabeth Anderson | F | 66 | 5 years | |
| Karen Adams | F | - | 3 years | |
| Julia Haller | M | 69 | 3 years | |
| Sushma Gambhir | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 years |
| Brian Kotzin | M | 74 | 5 years | |
| Kevin Haas | M | 38 | 6 years | |
| Ryan Jones | M | 36 | 6 years | |
| Betsy Santos | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 5 years |
| Sekar Kathiresan | M | 52 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 2 years |
| Javier Szwarcberg | M | 54 | 2 years | |
| Glenn Farrell | M | - | 2 years | |
| Dennis Joseph Slamon | M | 75 | 10 years | |
| Thomas P. Slavin | M | - | 4 years | |
| David Pyott | M | 70 | 8 years | |
| Samir Gharib | M | 41 | 4 years | |
| Peter Maag | M | 56 | 2 years | |
| Robert Hombach | M | 58 | 7 years | |
| Ian Clark | M | 62 | 3 years | |
| Lee Newcomer | M | 71 | 5 years | |
| Colleen Reitan | F | 64 | 5 years | |
| Heiner Dreismann | M | 69 | 14 years | |
| Catherine Sohn | M | 71 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 3 years |
| Tiba Aynechi | M | 48 | 8 years | |
| Daniel Skovronsky | M | 50 | 4 years | |
| Steve Liapis | M | 36 | 2 years | |
| Percival Barretto-Ko | M | 51 | 1 years | |
| Kirk Ways | M | 72 | 3 years | |
| J. Whitaker | M | 68 | 14 years | |
| Beth Seidenberg | M | 67 | 6 years | |
| Niall O'Donnell | M | 51 | 8 years | |
| Steve Kelsey | M | 63 | 4 years | |
| Jeremy Levin | M | 70 | 4 years | |
| John Oberg | M | - | 1 years | |
| Bruno Gagnon | M | - | 2 years | |
| Timothy M. Duffy | M | 63 | 14 years | |
| Donald R. Stanski | M | 74 |
Stanford University
| 45 years |
| Paul Bisaro | M | 63 | 2 years | |
| Samraat Raha | M | 52 | 1 years | |
| Robert Stein | M | 73 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 6 years |
| Jeffrey Pfeffer | M | 77 |
Stanford University
| 45 years |
| Michael Dybbs | M | 49 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 7 years |
| Frédéric Guerard | M | 51 | 1 years | |
| Susan Orr | M | - | 2 years | |
| Quinton Oswald | M | - | 2 years | |
| Portia Serame | F | - | - | |
| Marcos Milla | M | 61 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert L. Kirkman | M | 75 |
Xcyte Therapies, Inc.
| 12 years |
| R. Riggsbee | M | 53 | 10 years | |
| John Orwin | M | 59 | 4 years | |
| Pierre LaPalme | M | 83 | 12 years | |
| Edward A. Taylor | M | 81 | 13 years | |
| Nancy Whiting | M | 51 | - | |
| Patrick Treanor | M | - | - | |
| Charlotte Arnold | F | - | - | |
| Scott Myers | M | 57 | 2 years | |
| Kenneth Hillan | M | 63 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 20 years |
| Mark Wood | M | 57 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 15 years |
| Arlene Morris | F | 72 | 8 years | |
| John Henderson | M | 79 | 16 years | |
| Ted Love | M | 65 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 12 years |
| William Young | M | 79 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 8 years |
| Walter A. Gilbert | M | 92 | 29 years | |
| Stephen Wurzburg | M | - |
Stanford University
| 8 years |
| Hollings Renton | M | 77 | 5 years | |
| Adora Ndu | M | 43 | 5 years | |
| G. Kirk Raab | M | 88 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 10 years |
| Sylvia R. Wheeler | F | 63 | - | |
| Claire J. Lockey | F | 71 | 5 years | |
| Tricia Borga Suvari | F | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 11 years |
| Chuck Hadley | M | - |
Stanford University
| 5 years |
| Ali Mahdavi | M | 71 | 5 years | |
| Mark Williams | M | 70 |
Stanford University
| 4 years |
| Abdullah Atalar | M | 70 |
Stanford University
| 3 years |
| Herbert Cross | M | 52 | 3 years | |
| Scott Rocklage | M | 69 | 7 years | |
| James Healy | M | 58 | 8 years | |
| John Butler | M | 59 | 3 years | |
| Ron Hunt | M | 59 | 2 years | |
| Keith Leonard | M | 62 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 91 | 91.92% |
| Australia | 8 | 8.08% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dan Spiegelman
- Personal Network
